<SEC-DOCUMENT>0001096906-23-001449.txt : 20230725
<SEC-HEADER>0001096906-23-001449.hdr.sgml : 20230725
<ACCEPTANCE-DATETIME>20230725144852
ACCESSION NUMBER:		0001096906-23-001449
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230725
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230725
DATE AS OF CHANGE:		20230725

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		231108147

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20230725.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD3L1RLS]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D230725' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D230725' id='fact2'>false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20230725.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D230725'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-07-25</i:startDate>
<i:endDate>2023-07-25</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:14pt Times New Roman;margin:0;text-align:center'><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'><b>Washington, D.C. &#160;20549</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>FORM <ix:nonNumeric name='dei:DocumentType' contextRef='D230725' escape='true'>8-K</ix:nonNumeric></b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>CURRENT REPORT</b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;text-align:center'><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>Date of Report (date of earliest event reported): &#160;<ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D230725' format='ixt:datemonthdayyearen'>July 25, 2023</ix:nonNumeric></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:468pt'><tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:14pt'><b><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D230725' escape='true'>UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D230725' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D230725' escape='true'>000-12575</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D230725' escape='true'>87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Commission File Number)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(IRS Employer</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>incorporation or organization)</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>Identification No.)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D230725' escape='true'>7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D230725' escape='true'>Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D230725' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D230725' escape='true'>84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Zip code)</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0'>Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b>Phone: </b><b>(</b><b><ix:nonNumeric name='dei:CityAreaCode' contextRef='D230725' escape='true'>801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D230725' escape='true'>566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:12pt Times New Roman;margin:0;text-align:center'><b>n/a</b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:WrittenCommunications' contextRef='D230725' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:SolicitingMaterial' contextRef='D230725' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementTenderOffer' contextRef='D230725' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementIssuerTenderOffer' contextRef='D230725' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Emerging growth company <ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D230725' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:11pt Times New Roman;margin:0'><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:72pt'>Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated July 25, 2023. &#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:72pt'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:72pt'>The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0'><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>The following is filed as an exhibit to this report: &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:100%'><tr><td valign='top' style='width:12.56%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Exhibit</b></p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Number*</b></p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:69.22%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Title of Document</b></p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.98%;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Location</b></p>
</td></tr>
<tr><td valign='top' style='background-color:#CCEEFF;width:12.56%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b>Item 99.1</b></p>
</td><td valign='top' style='background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:69.22%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><span style='font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex99z1.htm' style='text-decoration:none'>Financial information for Utah Medical Products, Inc. for the three and six months ended June 30, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated July 25, 2023.</a></span></p>
</td><td valign='top' style='background-color:#CCEEFF;width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='background-color:#CCEEFF;width:12.98%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:12.56%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:69.22%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:2.62%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:12.98%;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>This filing</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>_______________________________________</p>
<p style='font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify'><kbd style='position:absolute;font:9pt Times New Roman;margin-left:-18pt'>*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><b>SIGNATURES</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Dated:  July 25, 2023</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>By:</p>
</td><td valign='top' style='width:218.05pt;border-bottom:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:218.05pt;border-top:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION FOR UTAH MEDICAL PRODUCTS, INC. FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND FORWARD-LOOKING STATEMENTS RELATING TO 2023 AND BEYOND AS PRESENTED IN A PRESS RELEASE DATED JULY 25, 2023.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD3L1RLS]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style=font-size:11pt><B>EXHIBIT 99.1</B></FONT><B> </B></P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023</B></P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:50%><P style='font:11pt Times New Roman;margin:0'>Contact: Brian Koopman (801) 566-1200</P>
</TD><TD valign=top style=width:50%><P align=right style='font:11pt Times New Roman;margin:0'>July 25, 2023</P>
</TD></TR>
</TABLE>
<P style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;Utah Medical Products, Inc. [Nasdaq: UTMD] achieved second calendar quarter (2Q) and first half (1H) 2023 financial results consistent with those anticipated in its beginning of year projections.</P>
<P style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;Because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. </P>
<P style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Overview of Results</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>In brief, consolidated total 1H 2023 revenues were only $366 lower compared to 1H 2022 despite $630 lower biopharmaceutical OEM sales post COVID-pandemic, which was anticipated at the beginning of the year. Despite the lower sales, and combined with continued supply chain disruption challenges, UTMD&#8217;s 1H gross profit margin improved, yielding total gross profit almost the same for the first half of the year. Operating Income, however, declined $715 (7.5%) as a result of unusual litigation expenses related to yet unresolved Filshie clip product liability claims in the U.S. However, because UTMD realized $1,236 higher interest income on its cash balances, Net Income for 1H 2023 was up 10% compared to 1H 2022. The following is an income statement line item comparison of 2Q and 1H 2023 with 2Q and 1H 2022, according to U.S. Generally Accepted Accounting Principles (US GAAP):</P>
<P style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:68%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0'>2Q</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0'>1H</P>
</TD></TR>
<TR><TD valign=top style=width:68%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(April &#8211;&nbsp;June)</FONT></P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(January-June)</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:68%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(4%)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(1%)</P>
</TD></TR>
<TR><TD valign=top style=width:68%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(5%)</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(1%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:68%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(12%)</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(7%)</P>
</TD></TR>
<TR><TD valign=top style=width:68%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Income Before Tax (EBT): </P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>(1%) </P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ 6% </P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:68%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ 2%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ 10%</P>
</TD></TR>
<TR><TD valign=top style=width:68%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;&#160;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 3%</P>
</TD><TD valign=top style=width:1%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&#160;&#160;</P>
</TD><TD valign=top style=width:15%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>+ 11%</P>
</TD></TR>
</TABLE>
<P style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Profit margins in 2Q and 1H 2023 compared to 2Q and 1H 2022 follow:</P>
<P style='font:8pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style='border-collapse:collapse;width:100%;border-bottom:0.5pt solid #000000'><TR><TD valign=top style=width:48.1%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0'>2Q 2023</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0'>2Q 2022</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0'>1H 2023</P>
</TD><TD valign=top style=width:11.92%><P align=center style='font:11pt Times New Roman;margin:0'>1H 2022</P>
</TD></TR>
<TR><TD valign=top style=width:48.1%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(Apr &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(Apr &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Jun)</FONT></P>
</TD><TD valign=top style=width:11.92%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>(Jan &#8211;&nbsp;Jun)</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.1%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (GP/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>60.1%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>60.7%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>61.4%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.92%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>60.9%</P>
</TD></TR>
<TR><TD valign=top style=width:48.1%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (OI/ sales): Income B4 </P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>34.4%</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>37.7%</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>34.9%</P>
</TD><TD valign=top style=width:11.92%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>37.2%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:48.1%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Tax Margin (EBT/ sales):</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>40.2%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>38.7%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>40.5%</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.92%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>37.8%</P>
</TD></TR>
<TR><TD valign=top style=width:48.1%><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income Margin (NI/ sales)<I>:</I></P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>32.6%</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>30.6%</P>
</TD><TD valign=top style=width:13.32%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>33.1%</P>
</TD><TD valign=top style=width:11.92%><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>29.7%</P>
</TD></TR>
</TABLE>
<P style='font:8pt Times New Roman;margin:0;margin-right:-6.5pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>The lower consolidated revenues were primarily attributable to a decline in sales to UTMD&#8217;s biopharmaceutical OEM customer, although the Company was also not able to meet certain direct U.S. demand due to lack of raw materials and third-party sterilization capacity constraints. Outside the U.S. (OUS) revenues were higher despite a stronger USD which reduced 1H 2023 foreign currency sales $188 in USD terms. UTMD was able to achieve its targeted GP margins with the help of recent price increases. The dilution in OI margin was due to $463 higher 1H 2023 litigation costs which are included in Operating Expense per US GAAP. However, higher interest income included in non-operating income more than offset the litigation costs, and allowed an expansion in EBT. The additional expansion in NI and EPS was due to a lower estimated income tax provision rate and fewer diluted shares due to share repurchases during 2Q 2022. &nbsp;Please see the income statements on the last page of this report. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0;margin-right:-6.5pt'>UTMD&#8217;s June 30, 2023 Balance Sheet continued strong, with no debt. Ending Cash and Investments were $84.6 million on June 30, 2023 compared to $75.1 million on December 31, 2022. &nbsp;The June 30, 2023 cash balance resulted after paying $2.1 million in cash dividends to stockholders, increasing non-cash working capital by $0.1 million (including inventories by $1.3 million) and making $0.4 million in capital expenditures during 1H 2023.  Please see the balance sheets on the last page of this report. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Revenues (sales)</FONT> -<FONT style='border-bottom:1px solid #000000'>2Q 2023 </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 2Q 2023 UTMD worldwide (WW) sales in USD terms were $562 (4.2%) lower than in 2Q 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In 2Q 2023, OUS sales growth continued to outperform domestic sales growth. In 2Q 2023 compared to 2Q 2022, OUS sales were $250 (+4.5%) higher and U.S. domestic sales were $812 (10.4%) lower. &nbsp;$445 of the $562 lower total 2Q sales were sales of pressure monitoring devices and accessories to UTMD&#8217;s largest OEM customer, shipped from both the U.S. and Ireland. &nbsp;WW 2Q Filshie device sales were $94 (+3.1%) higher.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The portion of OUS sales invoiced in foreign currencies in USD terms were 33% of total WW consolidated 2Q 2023 sales compared to 29% in 2Q 2022. An average lower USD foreign currency exchange (FX) rate added $35 (+0.3%) for 2Q sales invoiced in foreign currencies. <A name=_Hlk108176647 />Actually, a stronger EUR by itself added $70. &nbsp;The GBP was about the same, and both the CAD and AUD were weaker. &nbsp;FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 2Q 2023 and 2Q 2022 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>2<FONT style='border-bottom:1px solid #000000'>Q 2022</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2531</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2525</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0845</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0571</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>+2.6%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6700</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7178</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( 6.7%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7449</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7847</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( 5.1%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The $35 weighted average favorable impact on 2Q 2023 foreign currency OUS sales was 0.8%. &nbsp;In constant currency terms, foreign currency sales in 2Q 2023 were 3.8% higher than in 2Q 2022. &#8220;Constant currency&#8221; sales means exchanging foreign currency sales into USD-denominated sales at the same FX rate as was in the previous period of time being compared. With a weaker USD in converting 2Q EUR foreign currency sales, WW constant currency sales were $597 lower (4.4%) than in 2Q 2022, which was the second highest sales quarter of 2022.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total OUS sales in 2Q 2023 were $5,849 compared to $5,599 in 2Q 2022. OUS sales invoiced in foreign currencies are due to direct end-user sales in Ireland, the UK, France, Canada, Australia and New Zealand, and to shipments to OUS distributors of products manufactured by UTMD subsidiaries in Ireland and the UK. &nbsp;Export sales from the U.S. to OUS distributors are invoiced in USD. &nbsp;Direct to end-user OUS 2Q 2023 sales in USD terms (including the impact of FX rate differences) were 13% higher in Ireland with the EUR FX rate up about 3%, 18% lower in Canada with the CAD FX rate down 5%, 10% higher in the UK with the GBP FX rate about the same, 19% lower in Australia/New Zealand with the AUD FX rate down 7%, and 3% higher in France with the EUR FX rate up 3%. USD-denominated sales to OUS distributors were 8% higher in 2Q 2023 than in 2Q 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 2Q 2023 were $7,017 compared to $7,829 in 2Q 2022. &nbsp;Domestic sales are invoiced in USD and not subject to FX rate fluctuations. The components of domestic sales include 1) &#8220;direct non-Filshie device sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;domestic Filshie device sales&#8221;. UTMD separates domestic Filshie device sales from other medical device sales direct to medical facilities </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style=font-size:11pt>because UTMD is simply a distributor for Femcare in the U.S.  Direct non-Filshie device sales, representing 52% of total domestic sales, were $326 (8.1%) lower in 2Q 2023 than in 2Q 2022. Direct U.S. sales, particularly for NICU devices, were hindered by continuing supply chain disruption on the availability of raw materials and a lack of third party sterilization capacity. Domestic OEM sales, representing 31% of total domestic sales, were $525 (19.6%) lower. Domestic Filshie device sales, representing 17% of total domestic sales, were $38 (+3.3%) higher in 2Q 2023 compared to 2Q 2022. </FONT></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT> -<FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1H 2023 UTMD WW sales in USD terms were $366 (1.4%) lower than in 1H 2022. Because an average stronger USD reduced 1H foreign currency sales by $188 (0.7%), constant currency 1H 2023 consolidated total sales were just $178 (0.7%) lower. Combined sales of pressure monitoring devices and accessories to UTMD&#8217;s largest OEM customer, shipped from the U.S. and Ireland were $630 lower in 1H 2023 compared to 1H 2022, more than accounting for the lower total sales. WW 1H 2023 Filshie device sales were $407 (+6.7%) higher.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>In 1H 2023, OUS sales growth continued to outperform domestic sales growth. In 1H 2023 compared to 1H 2022, OUS sales were $1,245 (+12.5%) higher and U.S. domestic sales were $1,611 (10.2%) lower. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total OUS sales in 1H 2023 were $11,184 compared to $9,938 in 1H 2022. The portion of OUS sales invoiced in foreign currencies in USD terms were 31% of total WW consolidated 1H 2023 sales compared to 26% in 1H 2022. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1H 2023 and 1H 2022 for revenue purposes follow:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1H<FONT style='border-bottom:1px solid #000000'> </FONT><BR><FONT style='border-bottom:1px solid #000000'>2023</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1H<FONT style='border-bottom:1px solid #000000'> </FONT><BR><FONT style='border-bottom:1px solid #000000'>2022</FONT></P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2329</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.2886</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;4.3%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0819</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>1.0852</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;0.3%)</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:25%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.6774</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7206</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;6.0%)</P>
</TD></TR>
<TR><TD valign=top style=width:25%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7419</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>0.7866</P>
</TD><TD valign=top style=width:25%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;5.7%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>The weighted-average FX rate negative impact on 1H 2023 foreign currency OUS sales was 2.4%. In constant currency terms, foreign currency sales in 1H 2023 were 18.2% higher than in 1H 2022. &nbsp;In constant currency terms, 1H 2023 OUS total sales were up 14.4%.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Direct to end-user OUS 1H 2023 sales in USD terms (including the impact of FX rate differences) were about the same in Ireland with the EUR FX rate also about the same, 10% lower in Canada with the CAD FX rate down 6%, 24% higher in the UK with the GBP FX rate down 4%, 11% lower in Australia/New Zealand with the AUD FX rate down 6%, and 10% higher in France with the EUR FX rate about the same as in 1H 2022. USD-denominated sales to OUS distributors were 15% higher in 1H 2023 than in 1H 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Domestic U.S. sales in 1H 2023 were $14,202 compared to $15,813 in 1H 2022. Direct non-Filshie device sales, representing 51% of total domestic sales, were $698 (8.7%) lower in 1H 2023 than in 1H 2022, led by a $567 decline in domestic neonatal device sales due to continued supply chain disruption. Domestic OEM sales, representing 32% of total domestic sales, were $900 (16.8%) lower. &nbsp;Domestic Filshie device sales, representing 17% of total domestic sales, were $13 (0.5%) lower in 1H 2023 compared to 1H 2022. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the cost of goods sold (CGS), comprised of costs of production, manufacturing engineering, depreciation of equipment, maintenance and repairs, quality assurance including regulatory compliance, and purchasing including freight for receiving materials from suppliers, from revenues. CGS is divided into three categories: direct labor, raw materials and manufacturing overhead. &nbsp;Direct labor and raw materials are predominantly variable costs, i.e. vary directly with revenues. &nbsp;MOH contains predominantly fixed costs relative to the Company&#8217;s infrastructure, for example, supervision and engineering personnel.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s 2Q 2023 GP was $412 (5.1%) lower than in 2Q 2022 due to a lower GP margin (GP divided by sales, GPM) on 4.2% lower sales. The 2Q 2023 GPM was 60.1% compared to 60.7% in 2Q 2022. 1H 2023 GP was just $102 (0.7%) lower than in 1H 2022, although sales were 1.4% lower, because UTMD&#8217;s GPM was higher in 1H 2023 than in 1H 2022. The 1H 2023 GPM was 61.4% compared to 60.9% in 1H 2022. &nbsp;UTMD&#8217;s 2023 GPMs remained consistent with long-term profitability goals. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Higher MOH costs with lower sales was the primary reason for the 2Q 2023 lower GPM, as a result of adding production supervision, engineering and management personnel, in addition to two cost-of-living increases for all manufacturing employees since the end of 2Q 2022. &nbsp;Incoming freight costs stabilized. &nbsp;Direct labor productivity was consistent with past periods of time, despite the cost-of-living increases due to price increases. Purchases of higher quantities of raw materials helped keep incremental raw material costs under relative control. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP.  OE are comprised of Sales and Marketing (S&amp;M) expenses, General and Administrative (G&amp;A) expenses and Product Development (R&amp;D) expenses. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI in 2Q 2023 of $4,425 was $632 (12.5%) lower compared to 2Q 2022 OI of $5,057. &nbsp;The $632 lower OI <A name=_Hlk140777717 />can be explained by $412 lower GP combined with $115 higher litigation expense (captured in the G&amp;A OE category) and $125 higher salaries included in WW OE categories (including payroll taxes and medical plan expense) for about the same number of people as in 2Q 2022. UTMD&#8217;s 2Q 2023 OI Margin (OI as a percentage of sales) remained a healthy 34.4%. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OI in 1H 2023 was $8,864 compared to $9,579 in 1H 2022, a decrease of $715 (7.5%), representing a healthy 1H 2023 OI margin of 34.9%. &nbsp;The decrease in 1H 2023 OI can be explained by $102 lower GP combined with $463 higher litigation expense and $207 higher salaries included in WW OE categories for about the same number of people as in 1H 2022. &nbsp;The higher salaries were from cost-of-living adjustments necessary to mitigate high inflation.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The following table summarizes OE in 2Q and 1H 2023 compared to the same periods in 2022 by OE category:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse><TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:54pt><P style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>2Q 2022</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>1H 2022</FONT></P>
</TD><TD valign=top style=width:52.4pt><P align=center style='font:11pt Times New Roman;margin:0'>% of <BR><FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:59.4pt><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:54pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:4pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:39pt'>405</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:43.8pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:27pt'>3.2</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:4pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>357</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>2.7</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:4pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>792</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>3.1</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:4pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>693</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:52.4pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>2.7</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:54pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:39pt'>2,775</KBD>&nbsp;</P>
</TD><TD valign=top style='width:43.8pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:27pt'>21.6</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>2,602</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>19.3</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>5,648</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>22.3</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>5,153</KBD>&nbsp;</P>
</TD><TD valign=top style=width:52.4pt><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>20.0</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:59.4pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:54pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:39pt'>133</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:43.8pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:27pt'>1.0</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>135</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-bottom:0.5pt solid #000000;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>1.0</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>277</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>1.1</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>258</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:52.4pt;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>1.0</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:59.4pt><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style='width:54pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:39pt'>3,313</KBD>&nbsp;</P>
</TD><TD valign=top style='width:43.8pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:27pt'>25.8</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>3,094</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>23.0</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>6,717</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>26.5</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:38pt'>6,104</KBD>&nbsp;</P>
</TD><TD valign=top style='width:52.4pt;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:35pt'>23.7</KBD>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>An average stronger USD helped decrease foreign currency OE when converted to USD by $4 in 2Q 2023 and $85 in 1H 2023, which were relatively minor impacts The following table summarizes &#8220;constant currency&#8221; OE in 2Q and 1H 2023 compared to the same periods in 2022 by OE category:</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:12.64%><P style='font:11pt Times New Roman;margin:0'>OE <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:11.46%><P style='font:11pt Times New Roman;margin:0'>2Q 2023 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=top style='width:9.26%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>2Q 2022</FONT></P>
</TD><TD valign=top style='width:11.08%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1H 2023 <BR><FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=top style='width:11.08%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>1H 2022</FONT></P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:12.64%><P style='font:11pt Times New Roman;margin:0'>S&amp;M:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:47pt'>406</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.26%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>357</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>799</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>693</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:12.64%><P style='font:11pt Times New Roman;margin:0'>G&amp;A:</P>
</TD><TD valign=top style=width:11.46%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:47pt'>2,778</KBD>&nbsp;</P>
</TD><TD valign=top style='width:9.26%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>2,602</KBD>&nbsp;</P>
</TD><TD valign=top style='width:11.08%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>5,725</KBD>&nbsp;</P>
</TD><TD valign=top style='width:11.08%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>5,153</KBD>&nbsp;</P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:12.64%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>R&amp;D:</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.46%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:47pt'>133</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:9.26%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>135</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>278</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.08%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.14%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>258</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:12.64%><P style='font:11pt Times New Roman;margin:0'>Total OE:</P>
</TD><TD valign=top style='width:11.46%;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:47pt'>3,317</KBD>&nbsp;</P>
</TD><TD valign=top style='width:9.26%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>3,094</KBD>&nbsp;</P>
</TD><TD valign=top style='width:11.08%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>6,802</KBD>&nbsp;</P>
</TD><TD valign=top style='width:11.08%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:11.14%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:45pt'>6,104</KBD>&nbsp;</P>
</TD><TD valign=top style=width:11.08%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>G&amp;A expenses dominate UTMD&#8217;s OE, largely because of non-cash expenses from the amortization of Identifiable Intangible Assets (IIA) associated with the Filshie Clip System, which were about 57% of G&amp;A expenses in 2023. &nbsp;A segmentation of USD-denominated G&amp;A expenses by subsidiary follows:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>2Q 2022</FONT></P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>1H 2022</FONT></P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>% of <FONT style='border-bottom:1px solid #000000'>sales</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>498</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:32pt'>3.9</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>498</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>3.7</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>981</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>3.9</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,030</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>4.0</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort&#8211; CSI:</P>
</TD><TD valign=top style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>1,105</KBD>&nbsp;</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:32pt'>8.6</KBD>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,105</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>8.2</KBD>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>2,210</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>8.7</KBD>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>2,210</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>8.6</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>163</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>142</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>327</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>296</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>U.S. Litigation</P>
</TD><TD valign=top style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>280</KBD>&nbsp;</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>165</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>689</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>226</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; US:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>588</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>528</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,150</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,082</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>69</KBD>&nbsp;</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>85</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>153</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>152</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>35</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>42</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>69</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>85</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=top style='width:12.48%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>37</KBD>&nbsp;</P>
</TD><TD valign=top style='width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>37</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:1.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>69</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>72</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.48%;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>2,775</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:8.32%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:32pt'>21.6</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>2,602</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>19.3</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-top:0.5pt solid #000000;border-left:1.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>5,648</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>22.2</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>5,153</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:29pt'>20.0</KBD>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>OUS G&amp;A expenses were $802 in 2Q 2023 compared to $804 in 2Q 2022. OUS G&amp;A expenses were $1,599 in 1H 2023 compared to $1,635 in 1H 2022. A stronger USD reduced OUS G&amp;A expenses by$2 in 2Q 2023 and by $76 in 1H 2023. The table below identifies &#8220;constant currency&#8221; OUS G&amp;A expenses for 2Q and 1H 2023 compared to the same periods in 2022:</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>G&amp;A Exp <BR><FONT style='border-bottom:1px solid #000000'>Category</FONT></P>
</TD><TD valign=top style=width:12.48%><P align=center style='font:11pt Times New Roman;margin:0'>2Q 2023 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=top style=width:8.32%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>2Q 2022</FONT></P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>1H 2023 <FONT style='border-bottom:1px solid #000000'>const FX</FONT></P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P align=center style='font:11pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'>1H 2022</FONT></P>
</TD><TD valign=top style=width:7.64%><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>IIA Amort- UK:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>498</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:8.32%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>498</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,030</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,030</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>Other&#8211; UK:</P>
</TD><TD valign=top style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>163</KBD>&nbsp;</P>
</TD><TD valign=top style=width:8.32%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>142</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>344</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>296</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'>IRE:</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>67</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:8.32%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>85</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>155</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>152</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>AUS:</P>
</TD><TD valign=top style=width:12.48%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>37</KBD>&nbsp;</P>
</TD><TD valign=top style=width:8.32%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>42</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>73</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:12.1%><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>85</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:19.96%><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>CAN:</FONT></P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.48%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>39</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:8.32%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>37</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>73</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:12.1%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>72</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:19.96%><P style='font:11pt Times New Roman;margin:0'>Total G&amp;A:</P>
</TD><TD valign=top style='width:12.48%;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:51pt'>804</KBD>&nbsp;</P>
</TD><TD valign=top style=width:8.32%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>804</KBD>&nbsp;</P>
</TD><TD valign=top style='width:7.64%;border-right:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,675</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style='width:12.1%;border-top:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:11pt Times New Roman;width:50pt'>1,635</KBD>&nbsp;</P>
</TD><TD valign=top style=width:7.64%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>S&amp;M OE were $48 and $99 higher in 2Q 2023 and 1H 2023 compared to the same periods in 2022 respectively. &nbsp;The differences were due to one additional S&amp;M person in the U.S. together with cost-of-living adjustments, offset slightly by $1 and $7 lower OUS S&amp;M expenses in 2Q 2023 and 1H 2023 respectively due to a stronger USD.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Period to period product development (R&amp;D) expenses varied slightly depending on specific project costs. Since almost all R&amp;D is being carried out in the U.S., there was negligible FX rate impact. &nbsp; </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT)</FONT> </P>
<P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:6pt'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. &nbsp;Consolidated 2Q 2023 EBT was $5,172 (40.2% of sales) compared to $5,199 (38.7% of sales) in 2Q 2022. Consolidated 1H 2023 EBT was $10,291 (40.5% of sales) compared to $9,729 (37.8% of sales) in 1H 2022.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms on June 30, 2023; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. Negative NOE is NOI. &nbsp;Net NOI in 2Q 2023 was $747 compared to $142 net NOI in 2Q 2022. Net NOI in 1H 2023 was $1,427 compared to $150 net NOI in 1H 2022. &nbsp;With higher cash balances and higher interest rates in 2023 compared to 2022, UTMD received more interest income.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBITDA is a non-US GAAP metric that measures profitability performance without factoring in effects of financing, accounting decisions regarding non-cash expenses, capital expenditures or tax environments. Management believes that this operating performance metric provides meaningful supplemental information to both management and investors and confirms UTMD&#8217;s ongoing excellent financial operating performance, as well as its ability to sustain performance during a challenging economic time. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 2Q 2023 consolidated EBT excluding the remeasured bank balance currency gain or loss (&#8220;adjusted consolidated EBITDA&#8221;) was $6,996 compared to $7,005 in 2Q 2022. &nbsp;Adjusted consolidated EBITDA at $13,916 in 1H 2023 was 4% higher compared to $13,376 in 1H 2022. Adjusted consolidated trailing twelve months&#8217; (TTM) EBITDA was $28,431 as of June 30, 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s adjusted consolidated EBITDA as a percentage of sales (EBITDA margin) was 54.4% in 2Q 2023 compared to 52.2% in 2Q 2022. UTMD&#8217;s EBITDA margin was 54.8% in 1H 2023 compared to 51.9% in 1H 2022. The higher 2023 EBITDA margins reflect that the increase in interest income on cash balances (non-operating income) was substantially higher than the increase in litigation expenses (G&amp;A OE). Management believes that current EBITDA margins demonstrate continued outstanding operating performance. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD&#8217;s non-US GAAP adjusted consolidated EBITDA is the sum of the elements in the following table, each element of which is a US GAAP number: &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:47.92%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2022</FONT></P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2022</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.92%><P style='font:11pt Times New Roman;margin:0'>EBT</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>$ 5,172</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$ 5,199</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$10,291</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'> $ 9,729</P>
</TD></TR>
<TR><TD valign=top style=width:47.92%><P style='font:11pt Times New Roman;margin:0'>Depreciation Expense</P>
</TD><TD valign=top style=width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>155</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>153</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>310</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>302</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.92%><P style='font:11pt Times New Roman;margin:0'>Femcare IIA Amortization Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>498</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>498</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>981</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>1,030</P>
</TD></TR>
<TR><TD valign=top style=width:47.92%><P style='font:11pt Times New Roman;margin:0'>CSI IIA Amortization Expense</P>
</TD><TD valign=top style=width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1,105</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2,211</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>2,211</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.92%><P style='font:11pt Times New Roman;margin:0'>Other Non-Cash Amortization Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>8</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>16</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>16</P>
</TD></TR>
<TR><TD valign=top style=width:47.92%><P style='font:11pt Times New Roman;margin:0'>Stock Option Compensation Expense</P>
</TD><TD valign=top style=width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>50</P>
</TD><TD valign=top style='width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>40</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>100</P>
</TD><TD valign=top style=width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>83</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:47.92%><P style='font:11pt Times New Roman;margin:0'>Interest Expense</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:11.46%><P align=right style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>- </P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.54%><P align=right style='font:11pt Times New Roman;margin:0'>-</P>
</TD></TR>
<TR><TD valign=top style='width:47.92%;border-bottom:0.5pt solid #000000'><P style='font:11pt Times New Roman;margin:0'>Remeasured Foreign Currency Balances</P>
</TD><TD valign=top style='width:11.46%;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8</P>
</TD><TD valign=top style='width:13.54%;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>2</P>
</TD><TD valign=top style='width:13.54%;border-left:0.5pt solid #000000;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>7</P>
</TD><TD valign=top style='width:13.54%;border-bottom:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>5</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:47.92%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>UTMD non-US GAAP EBITDA:</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:11.46%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$6,996</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-top:0.5pt solid #000000;border-right:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$7,005</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-top:0.5pt solid #000000;border-left:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$13,916</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:13.54%;border-top:0.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>$13,376</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT> </P>
<P style='font:11pt Times New Roman;margin:0'><A name=_Hlk140828510 />Despite slightly lower EBT, NI in 2Q 2023 of $4,200 (32.6% of sales) was 2.3% higher than the NI of $4,103 (30.6% of sales) in 2Q 2022. &nbsp;The higher NI was due to a greater proportion of UTMD&#8217;s EBT generated in Ireland with the lowest corporate income tax rate and a portion of U.S. non-operating income being federally tax-exempt, offset by a higher UK corporate tax rate beginning with 2Q 2023. The average consolidated income tax provision rate (as a % of the same period EBT) in 2Q 2023 was 18.8% compared to 21.1% in 2Q 2022.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'>Because 1H 2023 EBT was 5.8% higher than in 1H 2022, 1H 2023 NI of $8,414 (33.1% of sales) obtained further leverage yielding 10.2% higher NI than the NI of $7,638 (29.7% of sales) in 1H 2022. &nbsp;The average consolidated income tax provision rate (as a % of the same period EBT) in 1H 2023 was 18.2% compared to 21.5% in 1H 2022.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The consolidated income tax provision rate varies as the mix in taxable income among U.S. and foreign subsidiaries with differing income tax rates differs from period to period. Except for the UK, in which the corporate income tax rate changed to 25% from 19% on April 1, 2023, the basic corporate income tax rates in each of the sovereignties were the same as in the prior year. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT></P>
<P style='font:11pt Times New Roman;margin:0'>Diluted EPS in 2Q 2023 were $1.154 compared to diluted EPS of $1.124 in 2Q 2022, a 2.7% increase. &nbsp;Diluted EPS in 1H 2023 were $2.313 compared to diluted EPS of $2.088 in 1H 2022, a 10.8% increase. The increases in EPS were higher than the increases in NI as a result of fewer diluted shares. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Diluted shares were 3,638,566 in 2Q 2023 compared to 3,650,242 in 2Q 2022. &nbsp;Diluted shares were 3,637,715 in 1H 2023 compared to 3,657,864 in 1H 2022. The lower diluted shares in both periods of 2023 were the result of shares repurchased during 2Q 2022, offset by employee options exercised and a slightly higher dilution factor for unexercised options. The number of shares added as a dilution factor in 2Q 2023 was 10,288 compared to 7,375 in 2Q 2022. The number of shares added as a dilution factor in 1H 2023 was 9,660 compared to 9,069 in 1H 2022.  </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The number of shares used for calculating EPS was higher than period-ending outstanding shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. Outstanding shares at the end of 2Q 2023 were 3,628,988 compared to 3,627,767 at the end of calendar year 2022. The difference was due to 1,221 shares added from employee option exercises during 1H 2023. For comparison, outstanding shares were 3,624,932 at the end of 2Q 2022. The total number of outstanding unexercised employee and outside director options at June 30, 2023 was 66,025 at an average exercise price of $73.78, including shares awarded but not yet vested. &nbsp;This compares to 50,408 unexercised option shares at the end of 2Q 2022 at an average exercise price of $69.07/ share, including shares awarded but not vested. Option awards totaling 20,600 shares were made to 40 employees in October 2022 at an exercise price of $82.60. &nbsp;No options have been awarded in 2023. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD paid $1,070 ($0.295/share) in dividends to stockholders in 2Q 2023 compared to $1,060 ($0.290/ share) paid in 2Q 2022. <A name=_Hlk140832217 />The dividends paid to stockholders during 2Q 2023 were 25% of NI. UTMD paid $2,140 ($0.295/share) in dividends to stockholders in 1H 2023 compared to $1,060 ($0.290/ share) paid in 1H 2022. The dividends paid to stockholders during 1H 2023 were also 25% of NI. The 1H 2022 dividend total excluded a dividend normally paid in January. A special dividend of $7,309 ($2.00/share) was paid in December 2021 in lieu of January 2022. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>UTMD has not repurchased its shares since 2Q 2022. In 2Q 2022, UTMD repurchased 30,105 shares for $2,495, an average cost of $82.88/ share. &nbsp;Those were the only share repurchases in 2022. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 2Q 2023 was $93.20, down 1.7% from the closing price of $94.77 at the end of 1Q 2023, and down 7.3% from the closing price of $100.53 at the end of 2022. &nbsp;The closing share price one year ago at the end of 2Q 2022 was $85.90. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At June 30, 2023 compared to the end of 2022, UTMD&#8217;s cash and investments increased $9,567 to $84,619 as a result of 1H 2023 NP of $8,414 less $2,140 use of cash for dividends to stockholders, coupled in particular with a $1,935 reduction in receivables. At June 30, 2023, net Intangible Assets decreased to 16.2% of total consolidated assets from 19.2% on December 31, 2022. UTMD&#8217;s strong 19.2 current ratio at June 30, 2023 was higher than the 15.1 current ratio at December 31, 2022 as a result of higher cash and inventory balances together with $933 lower accrued liabilities. The average age of trade receivables was 25 days from date of invoice at June 30, 2023 compared to 37 days at December 31, 2022, based on the most recent calendar quarter of sales. Average inventory turns declined to 2.0 in 2Q 2023 compared to 2.5 for the last quarter of 2022 due to continued increases in safety stocks of raw material.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Foreign currency exchange (FX) rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 2Q 2023 compared to the end of calendar year 2022 and the end of 2Q 2022 were</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:13.46%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6-30-23</FONT></P>
</TD><TD valign=top style=width:14.9%><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>12-31-22</FONT></P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>6-30-22</FONT></P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:20.04%><P style='font:11pt Times New Roman;margin:0'>GBP</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.46%><P align=right style='font:11pt Times New Roman;margin:0'>1.27084</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.9%><P align=right style='font:11pt Times New Roman;margin:0'>1.20771</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;5.2%</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.21601</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.5%</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>EUR</P>
</TD><TD valign=top style=width:13.46%><P align=right style='font:11pt Times New Roman;margin:0'>1.09178</P>
</TD><TD valign=top style=width:14.9%><P align=right style='font:11pt Times New Roman;margin:0'>1.06940</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.1%</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>1.04657</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;4.3%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:20.04%><P style='font:11pt Times New Roman;margin:0'>AUD</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:13.46%><P align=right style='font:11pt Times New Roman;margin:0'>0.66614</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.9%><P align=right style='font:11pt Times New Roman;margin:0'>0.68050</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;2.1%)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.69042</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>(  3.5%)</P>
</TD></TR>
<TR><TD valign=top style=width:20.04%><P style='font:11pt Times New Roman;margin:0'>CAD</P>
</TD><TD valign=top style=width:13.46%><P align=right style='font:11pt Times New Roman;margin:0'>0.75547</P>
</TD><TD valign=top style=width:14.9%><P align=right style='font:11pt Times New Roman;margin:0'>0.73899</P>
</TD><TD valign=top style='width:17.2%;border-right:1.5pt solid #000000'><P align=center style='font:11pt Times New Roman;margin:0'> &nbsp;2.2%</P>
</TD><TD valign=top style='width:14.9%;border-left:1.5pt solid #000000'><P align=right style='font:11pt Times New Roman;margin:0'>0.77691</P>
</TD><TD valign=top style=width:19.5%><P align=center style='font:11pt Times New Roman;margin:0'>( &nbsp;2.8%)</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Financial ratios as of June 30, 2023 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 19.2&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 2Q 2023 sales activity) = 25&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 2Q 2023 CGS) = 2.0&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2023 YTD ROE (before dividends) = 14%&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0'><FONT style=font-size:13pt><B>Utah Medical Products, Inc.</B></FONT></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, Second Quarter (three months ended June 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share):</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:39.4%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:18.94%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2023</FONT></P>
</TD><TD valign=top style=width:19.74%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>2Q 2022</FONT></P>
</TD><TD valign=top style=width:21.92%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:39.4%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:18.94%><P align=right style='font:10pt Times New Roman;margin:0'>$ 12,866</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:19.74%><P align=right style='font:10pt Times New Roman;margin:0'>$ 13,428</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:21.92%><P align=right style='font:10pt Times New Roman;margin:0'>(4.2%)</P>
</TD></TR>
<TR><TD valign=top style='width:39.4%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:18.94%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,739</P>
</TD><TD valign=top style='width:19.74%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>8,151</P>
</TD><TD valign=top style='width:21.92%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(5.1%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:39.4%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.94%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,425</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.74%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,057</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.92%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(12.5%)</P>
</TD></TR>
<TR><TD valign=top style='width:39.4%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:18.94%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,172</P>
</TD><TD valign=top style='width:19.74%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>5,199</P>
</TD><TD valign=top style='width:21.92%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(0.5%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:39.4%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.94%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,200</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.74%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>4,103</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.92%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>+ 2.3%</P>
</TD></TR>
<TR><TD valign=top style='width:39.4%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style='width:18.94%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$&#160; 1.154</P>
</TD><TD valign=top style='width:19.74%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$&#160;&#160;1.124</P>
</TD><TD valign=top style='width:21.92%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>+ 2.7%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:39.4%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:18.94%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,639</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:19.74%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,650</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.92%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>INCOME STATEMENT, First Half (six months ended June 30)</P>
<P style='font:10pt Times New Roman;margin:0'>(in thousands except earnings per share): </P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:37.76%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2023</FONT></P>
</TD><TD valign=top style=width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1H 2022</FONT></P>
</TD><TD valign=top style=width:21.46%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:37.76%><P style='font:10pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.58%><P align=right style='font:10pt Times New Roman;margin:0'>$ 25,386</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:20.2%><P align=right style='font:10pt Times New Roman;margin:0'>$ 25,752</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:21.46%><P align=right style='font:10pt Times New Roman;margin:0'>(1.4%)</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>15,581</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>15,683</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(0.7%)</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>8,864</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9,579</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>(7.5%)</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>10,291</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>9,729</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>+ 5.8%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>8,414</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>7,638</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>+ 10.2%</P>
</TD></TR>
<TR><TD valign=top style='width:37.76%;border-bottom:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style='width:20.58%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$&#160;&#160;2.313</P>
</TD><TD valign=top style='width:20.2%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>$ &#160;2.088</P>
</TD><TD valign=top style='width:21.46%;border-bottom:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>+ 10.8%</P>
</TD></TR>
<TR><TD valign=top style='background-color:#CCEEFF;width:37.76%;border-top:0.5pt solid #000000'><P style='font:10pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.58%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,637</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:20.2%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>3,658</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:21.46%;border-top:0.5pt solid #000000'><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse;width:100%><TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited) &nbsp;</P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited) &nbsp;</P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>(audited)</P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>(unaudited)</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2023</FONT></P>
</TD><TD valign=top style=width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2023</FONT></P>
</TD><TD valign=top style=width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2022</FONT></P>
</TD><TD valign=top style=width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>JUN 30, 2022</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P align=right style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>84,619</KBD>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>80,912</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>75,052</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>66,224</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>3,603</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>3,818</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>5,538</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>4,938</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Inventories</P>
</TD><TD valign=top style=width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>10,118</KBD>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>9,940</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>8,814</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>7,338</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Other Current Assets</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>467</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>442</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>515</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>453</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style='width:14.32%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>98,807</KBD>&nbsp;</P>
</TD><TD valign=top style='width:15.12%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>95,112</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.58%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>89,919</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.92%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>78,953</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>10,541</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>10,241</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>10,224</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>10,591</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style='width:14.32%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>21,127</KBD>&nbsp;</P>
</TD><TD valign=top style='width:15.12%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>22,417</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.58%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>23,731</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.92%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>26,605</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>130,475</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>127,770</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>123,874</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>116,149</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=width:14.32%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>1,336</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>1,027</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>1,218</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>818</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>419</KBD>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>419</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>419</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>220</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>3,389</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>4,628</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>4,323</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>3,401</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style='width:14.32%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>5,144</KBD>&nbsp;</P>
</TD><TD valign=top style='width:15.12%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>6,074</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.58%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>5,960</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.92%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>4,439</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangible Assets</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>1,370</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>1,456</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>1,513</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>1,707</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Long Term Lease Liability </P>
</TD><TD valign=top style=width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>315</KBD>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>328</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>341</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>368</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>1,256</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>1,256</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>1,256</KBD>&nbsp;</P>
</TD><TD valign=top style=background-color:#CCEEFF;width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>1,675</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'>Deferred Revenue and Income Taxes</P>
</TD><TD valign=top style=width:14.32%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>628</KBD>&nbsp;</P>
</TD><TD valign=top style=width:15.12%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>638</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.58%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>549</KBD>&nbsp;</P>
</TD><TD valign=top style=width:14.92%><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>489</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#CCEEFF;width:41.04%><P style='font:10pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.32%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>121,762</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:15.12%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>118,018</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.58%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>114,255</KBD>&nbsp;</P>
</TD><TD valign=top style='background-color:#CCEEFF;width:14.92%;border-bottom:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>107,471</KBD>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:41.04%><P style='font:10pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style='width:14.32%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:60pt'>130,475</KBD>&nbsp;</P>
</TD><TD valign=top style='width:15.12%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:64pt'>127,770</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.58%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:61pt'>123,874</KBD>&nbsp;</P>
</TD><TD valign=top style='width:14.92%;border-top:0.75pt solid #000000'><P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:7pt'>$</KBD><KBD style='position:absolute;text-align:right;font:10pt Times New Roman;width:63pt'>116,149</KBD>&nbsp;</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20230725_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD3L1RLS]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230725"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230725.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20230725_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD3L1RLS]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230725"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20230725_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD3L1RLS]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230725"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230725.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20230725.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD3L1RLS]. www.edgarsuite.com -->
<schema xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2023' xmlns:fil='http://utahmed.com/20230725' xmlns:dei='http://xbrl.sec.gov/dei/2023' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://utahmed.com/20230725' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230725_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230725_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230725_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2022-03-31/types.xsd' namespace='http://www.xbrl.org/dtr/type/2022-03-31'/>
	<import namespace='http://xbrl.sec.gov/dei/2023' schemaLocation='https://xbrl.sec.gov/dei/2023/dei-2023.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2023' schemaLocation='https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140278670234320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Jul. 25,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>utmd-20230725_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20230725.xsd" xlink:type="simple"/>
    <context id="D230725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-07-25</startDate>
            <endDate>2023-07-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D230725" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D230725" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D230725">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D230725">2023-07-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D230725">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D230725">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D230725">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D230725">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D230725">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D230725">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D230725">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D230725">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D230725">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D230725">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D230725">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D230725">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D230725">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D230725">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D230725">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/UY_ 5!+ 0(4 Q0    ( !EV^58'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ &7;Y5B1ZHD+O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ &7;Y5IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  9=OE60;I5%^,#  "7#@  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ &7;Y5I^@&_"Q @  X@P   T              ( !)PP  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  9=OE6EXJ[',     3 @  "P
M    @ $##P  7W)E;',O+G)E;'-02P$"% ,4    "  9=OE6'#AEZC\!   \
M @  #P              @ 'L#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ &7;Y5B0>FZ*M    ^ $  !H              ( !6!$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ &7;Y5F60>9(9 0  SP,
M !,              ( !/1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  AQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20230725.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="utmd-20230725.htm">utmd-20230725.htm</File>
    <File>utmd-20230725.xsd</File>
    <File>utmd-20230725_def.xml</File>
    <File>utmd-20230725_lab.xml</File>
    <File>utmd-20230725_pre.xml</File>
    <File>utmd_ex99z1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20230725.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 19
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "utmd-20230725_def.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20230725.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20230725_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20230725_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20230725.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 34,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 19,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20230725",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230725.htm",
      "contextRef": "D230725",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230725.htm",
      "contextRef": "D230725",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Fiscal Year End"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Period End date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "SEC Form"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Registrant CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Number of common stock shares outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Current with reporting"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Tax Identification Number (TIN)"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Trading Exchange"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://utahmed.com/20230725/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-23-001449-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-23-001449-xbrl.zip
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MNGJ\_K1J1H74EQT1]JF"^4%(><.T#?MX!H@!=)D#-*;34W!.C*PUAA.I<.E
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M:F> _QE)L!RC>>B*MCTVKW\-1W@>#20KC1\>*&P5PE\7:.?)@$+\ 22[UUV
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MK3[*OGAYV%?8YY+TE$G^5PO]'V.<__!_4$L#!!0    ( !EV^5;/($[^U0(
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MIVC.A-:H6O@YR1IUH8!^XAVW?M[\B\0%9$_29G\=E1*3-"[2 V46)^5EN,&
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MNB:]/]_)&\P?\\\DYSO_ E!+ P04    "  9=OE629ZL>%TZ  "?* ( #P
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M</P2R*VD3($*R W&Y!X>Q>DC2H\'L#1]G-@+&4_ 1C%T(R\. \XX+O #??
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M^&G6V($OZTA)9NF8BJFO<7[(FS0+$*R[AA&.#%O=^(BXA "U/E^9BM:V2B9
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M')-OOVZ:%93N3\\GSFSK+"NHO4W'5X']<7?6O6GPWE!;S:)866$\(P;2ML]
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M<K&3+ZMV=\EN1+5O4"#VJC7R1/;D#%+_%=#678$].:7LR0JL<P[?DV/,GJQ
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ME<BAL>N(CA9\,\FYP$2MK? /L><R.X')O43359!">^'S:<T?NLK#^:;GM*M
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MX#BG5^?_Q'\_W7[^[?U__1]02P$"% ,4    "  9=OE6GP78N5,.  #)9@
M$0              @ $     =71M9"TR,#(S,#<R-2YH=&U02P$"% ,4
M"  9=OE6SR!._M4"   ^"0  $0              @ &"#@  =71M9"TR,#(S
M,#<R-2YX<V102P$"% ,4    "  9=OE60NDE]!8"   F!P  %0
M    @ &&$0  =71M9"TR,#(S,#<R-5]D968N>&UL4$L! A0#%     @ &7;Y
M5KLEU1PA"   TDX  !4              ( !SQ,  '5T;60M,C R,S W,C5?
M;&%B+GAM;%!+ 0(4 Q0    ( !EV^5;TX O0IP4  $8T   5
M  "  2,<  !U=&UD+3(P,C,P-S(U7W!R92YX;6Q02P$"% ,4    "  9=OE6
M29ZL>%TZ  "?* ( #P              @ '](0  =71M9%]E>#DY>C$N:'1M
64$L%!@     &  8 A $  (=<      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
